nach oben

Erschienen in:

18.07.2018 | Review

Novel frontiers in detecting cancer metastasis

verfasst von: Stanley P. Leong, Carmen Ballesteros-Merino, Shawn M. Jensen, Sebastian Marwitz, Carlo Bifulco, Bernard A. Fox, Mojca Skoberne

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5-6/2018

Einloggen, um Zugang zu erhalten

Abstract

Cancer microenvironment is the critical battle ground between the cancer cells and host response. Thus, more emphasis is directed to study the relationship between cancer cells and the stromal cells. Multiplex microscopy is an emerging technique in which multiple cell populations within the cancer microenvironment may be stained so that spatial relationship between cancer cells and, in particular, the immune cells may be studied during different stages of cancer development. Recent discovery of mutational burden and neoantigens in cancer has opened new landscapes in the interaction of host immune cells and cancer neoantigens. The emerging role of miRNAs may become an added dimension to study cancer beyond traditional pathway of DNA directed RNA being associated with the malignant behavior of cancer. Circulating tumor cells, cancer markers and ctDNA can be used as markers for circulating cancer cells in the blood. Further studies are needed to validate if liquid biopsy of cancer may become a routine clinical tool to screen cancer or follow patients for recurrence or responses to treatment.

Pardo DM (2012) Multiple co-stimulatory and inhibitory interactions regulate T cell responses. Nat Rev Cancer 12:252CrossRef

Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74CrossRef

Ito A, Kitano S et al (2015) Cancer neoantigens: a promising source of immunogens for cancer immunotherapy. J Clin Cell Immunol 6(322):2

Virchow R (1863) Cellular pathology as based upon physiological and pathological histology. Philadelphia: J.B. Lippincott

Handley WS (1907) The pathology of melanotic growths in relation to their operative treatment. Lancet 169:996–1003CrossRef

Bethmann D, Feng Z, Fox BA (2017) Immunoprofiling as a predictor of patient’s response to cancer therapy-promises and challenges. Curr Opin Immunol 45:60–72CrossRef

Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRef

Galon J, Pages F, Marincola FM et al (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205CrossRef

Pages F, Mlecnik B, Marliot F et al (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128–2139CrossRef

10.

Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337CrossRef

11.

Page DB, Hulett TW, Hilton TL et al (2016) Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine. J Immunother Cancer 4:25CrossRef

12.

Mlecnik B, Van den Eynde M, Bindea G et al (2018) Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst 110

13.

Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222CrossRef

14.

Yuan J (2016) Circulating protein and antibody biomarker for personalized cancer immunotherapy. J Immunother Cancer 4:46CrossRef

15.

Feng Z, Puri S, Moudgil T et al (2015) Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer 3:47CrossRef

16.

LaCelle MG, Jensen SM, Fox BA (2009) Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 15:6881–6890CrossRef

17.

Feng Z, Bethmann D, Kappler M et al (2017) Multiparametric immune profiling in HPV-oral squamous cell cancer. JCI Insight 2

18.

Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell 171:934–949CrossRef

19.

Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med 375(9):819–829CrossRef

20.

Hulett TW, Jensen SM, Wilmarth PA et al (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J ImmunoTher Cancer 6(1):27. https://doi.org/10.1186/s40425-018-0331-0 CrossRefPubMedPubMedCentral

21.

Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199CrossRef

22.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128CrossRef

23.

Robbins PF, Lu YC, El-Gamil M et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752CrossRef

24.

van Rooij N, van Buuren MM, Philips D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439–e442CrossRef

25.

Bassani-Sternberg M, Braunlein E, Klar R et al (2016) Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 7:13404CrossRef

26.

Karpanen T, Olweus J (2017) The potential of donor T-cell repertoires in neoantigen-targeted cancer immunotherapy. Front Immunol 8:1718CrossRef

27.

Abelin JG, Keskin DB, Sarkizova S et al (2017) Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46:315–326CrossRef

28.

Vita R, Overton JA, Greenbaum JA et al (2015) The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43:D405–D412CrossRef

29.

Andreatta M, Nielsen M (2016) Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32:511–517CrossRef

30.

Rubinsteyn A, O’Donnell T, Damaraju N, Hammerbacher J (2016) Predicting peptide-MHC binding affinities with imputed training data. bioRxiv. https://doi.org/10.1101/054775 CrossRef

31.

Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ et al (2015) Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics 14:658–673CrossRef

32.

Yadav M, Jhunjhunwala S, Phung QT et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572–576CrossRef

33.

Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265–276CrossRef

34.

Stronen E, Toebes M, Kelderman S et al (2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352:1337–1341CrossRef

35.

Sahin U, Derhovanessian E, Miller M et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222–226CrossRef

36.

Kochenderfer JN, Somerville RPT, Lu T et al (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35:1803–1813CrossRef

37.

Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528CrossRef

38.

Stevanovic S, Draper LM, Langhan MM et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543–1550CrossRef

39.

Ott PA, Hu Z, Keskin DB et al (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217–221CrossRef

40.

Mensah VA, Gueye A, Ndiaye M et al (2016) Safety, immunogenicity and efficacy of prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP against Plasmodium falciparum infection in adults in senegal. PLoS ONE 11:e0167951CrossRef

41.

Reddy KB (2015) MicroRNA (miRNA) in cancer. Cancer Cell Int 15:38CrossRef

42.

Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469CrossRef

43.

Peng Y, Croce CM (2016) The role of MicroRNAs in human cancer. Signal Transduct Target Ther 1:15004CrossRef

44.

Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4:199–227CrossRef

45.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRef

46.

Weinberg RA (2007) The biology of cancer; Garland Science

47.

Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791CrossRef

48.

Zhang L, Riethdorf S, Wu G et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18:5701–5710CrossRef

49.

Cristofanilli M, Hayes DF, Budd GT et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430CrossRef

50.

de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309CrossRef

51.

Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221CrossRef

52.

Koyanagi K, O’Day SJ, Boasberg P et al (2010) Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402–2408CrossRef

53.

Zhang L, Riethdorf S, Wu G et al (2012) Metaanalysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18:5701–5710CrossRef

54.

Hayashi N, Yamauchi H (2012) Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer 19:110–117CrossRef

55.

Ignatiadis M, Kallergi G, Ntoulia M et al (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 14:2593–2600CrossRef

56.

Xenidis N, Ignatiadis M, Apostolaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27:2177–2184CrossRef

57.

Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P (2010) Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 102:1327–1334CrossRef

58.

Rahbari NN, Aigner M, Thorlund K et al (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138:1714–1726CrossRef

59.

Hoshimoto S, Faries MB, Morton DL et al (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357–362CrossRef

60.

Merker JD, Oxnard GR, Compton C et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical oncology and college of American pathologists joint review. J Clin Oncol 36:1–11CrossRef

Titel: Novel frontiers in detecting cancer metastasis
verfasst von: Stanley P. Leong
Carmen Ballesteros-Merino
Shawn M. Jensen
Sebastian Marwitz
Carlo Bifulco
Bernard A. Fox
Mojca Skoberne
Publikationsdatum: 18.07.2018
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 5-6/2018
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9918-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Novel frontiers in detecting cancer metastasis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5-6/2018

Future perspectives: cancer metastases

Regional therapies for locoregionally advanced and unresectable melanoma

Metastatic gynecologic malignancies: advances in treatment and management

Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials

Lymphedema following cancer therapy: overview and options

Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie